Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium

Abstract Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administratio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	François Boemer, Jean-Hubert Caberg, Pablo Beckers, Vinciane Dideberg, Samantha di Fiore, Vincent Bours, Sandrine Marie, Joseph Dewulf, Lionel Marcelis, Nicolas Deconinck, Aurore Daron, Laura Blasco-Perez, Eduardo Tizzano, Mickaël Hiligsmann, Jacques Lombet, Tatiana Pereira, Lucia Lopez-Granados, Sarvnaz Shalchian-Tehran, Véronique van Assche, Arabelle Willems, Sofie Huybrechts, Bénédicte Mast, Rudolf van Olden, Tamara Dangouloff, Laurent Servais
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aee7b58b35494c7a81456a3ae885e5c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aee7b58b35494c7a81456a3ae885e5c8
record_format	dspace
spelling	oai:doaj.org-article:aee7b58b35494c7a81456a3ae885e5c82021-12-02T18:37:10ZThree years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium10.1038/s41598-021-99496-22045-2322https://doaj.org/article/aee7b58b35494c7a81456a3ae885e5c82021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99496-2https://doaj.org/toc/2045-2322Abstract Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been initiated in several countries. In 2018, we launched a 3-year pilot program to screen newborns for SMA in the Belgian region of Liège. This program was rapidly expanding to all of Southern Belgium, a region of approximately 55,000 births annually. During the pilot program, 136,339 neonates were tested for deletion of exon 7 of SMN1, the most common cause of SMA. Nine SMA cases with homozygous deletion were identified through this screen. Another patient was identified after presenting with symptoms and was shown to be heterozygous for the SMN1 exon 7 deletion and a point mutation on the opposite allele. These ten patients were treated. The pilot program has now successfully transitioned into the official neonatal screening program in Southern Belgium. The lessons learned during implementation of this pilot program are reported.François BoemerJean-Hubert CabergPablo BeckersVinciane DidebergSamantha di FioreVincent BoursSandrine MarieJoseph DewulfLionel MarcelisNicolas DeconinckAurore DaronLaura Blasco-PerezEduardo TizzanoMickaël HiligsmannJacques LombetTatiana PereiraLucia Lopez-GranadosSarvnaz Shalchian-TehranVéronique van AsscheArabelle WillemsSofie HuybrechtsBénédicte MastRudolf van OldenTamara DangouloffLaurent ServaisNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q François Boemer Jean-Hubert Caberg Pablo Beckers Vinciane Dideberg Samantha di Fiore Vincent Bours Sandrine Marie Joseph Dewulf Lionel Marcelis Nicolas Deconinck Aurore Daron Laura Blasco-Perez Eduardo Tizzano Mickaël Hiligsmann Jacques Lombet Tatiana Pereira Lucia Lopez-Granados Sarvnaz Shalchian-Tehran Véronique van Assche Arabelle Willems Sofie Huybrechts Bénédicte Mast Rudolf van Olden Tamara Dangouloff Laurent Servais Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
description	Abstract Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been initiated in several countries. In 2018, we launched a 3-year pilot program to screen newborns for SMA in the Belgian region of Liège. This program was rapidly expanding to all of Southern Belgium, a region of approximately 55,000 births annually. During the pilot program, 136,339 neonates were tested for deletion of exon 7 of SMN1, the most common cause of SMA. Nine SMA cases with homozygous deletion were identified through this screen. Another patient was identified after presenting with symptoms and was shown to be heterozygous for the SMN1 exon 7 deletion and a point mutation on the opposite allele. These ten patients were treated. The pilot program has now successfully transitioned into the official neonatal screening program in Southern Belgium. The lessons learned during implementation of this pilot program are reported.
format	article
author	François Boemer Jean-Hubert Caberg Pablo Beckers Vinciane Dideberg Samantha di Fiore Vincent Bours Sandrine Marie Joseph Dewulf Lionel Marcelis Nicolas Deconinck Aurore Daron Laura Blasco-Perez Eduardo Tizzano Mickaël Hiligsmann Jacques Lombet Tatiana Pereira Lucia Lopez-Granados Sarvnaz Shalchian-Tehran Véronique van Assche Arabelle Willems Sofie Huybrechts Bénédicte Mast Rudolf van Olden Tamara Dangouloff Laurent Servais
author_facet	François Boemer Jean-Hubert Caberg Pablo Beckers Vinciane Dideberg Samantha di Fiore Vincent Bours Sandrine Marie Joseph Dewulf Lionel Marcelis Nicolas Deconinck Aurore Daron Laura Blasco-Perez Eduardo Tizzano Mickaël Hiligsmann Jacques Lombet Tatiana Pereira Lucia Lopez-Granados Sarvnaz Shalchian-Tehran Véronique van Assche Arabelle Willems Sofie Huybrechts Bénédicte Mast Rudolf van Olden Tamara Dangouloff Laurent Servais
author_sort	François Boemer
title	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
title_short	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
title_full	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
title_fullStr	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
title_full_unstemmed	Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
title_sort	three years pilot of spinal muscular atrophy newborn screening turned into official program in southern belgium
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/aee7b58b35494c7a81456a3ae885e5c8
work_keys_str_mv	AT francoisboemer threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT jeanhubertcaberg threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT pablobeckers threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT vincianedideberg threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT samanthadifiore threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT vincentbours threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT sandrinemarie threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT josephdewulf threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT lionelmarcelis threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT nicolasdeconinck threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT auroredaron threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT laurablascoperez threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT eduardotizzano threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT mickaelhiligsmann threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT jacqueslombet threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT tatianapereira threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT lucialopezgranados threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT sarvnazshalchiantehran threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT veroniquevanassche threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT arabellewillems threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT sofiehuybrechts threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT benedictemast threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT rudolfvanolden threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT tamaradangouloff threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium AT laurentservais threeyearspilotofspinalmuscularatrophynewbornscreeningturnedintoofficialprograminsouthernbelgium
_version_	1718377821356687360

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium

Ejemplares similares